A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma RRMM Who Have Normal and Varying Degrees of Impaired Renal Function DREAMM 12

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT04398745

Study #:
STUDY00146191

Start Date:
Feb 09, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04398745

View Complete Trial Details & Eligibility at ClinicalTrials.gov